Collegium Pharmaceutical Announces Relocation to New Facility in Rhode Island.Business Editors/Health/Medical Writers CUMBERLAND, R.I.--(BUSINESS WIRE)--Oct. 9, 2003 Collegium col·le·gi·um n. pl. col·le·gi·a or col·le·gi·ums 1. An executive council or committee of equally empowered members, especially one supervising an industry, commissariat, or other organization in the Soviet Union. Pharmaceutical, Inc., a closely held A phrase used to describe the ownership, management, and operation of a corporation by a small group of people. In a closely held corporation, the same people often act as shareholders, directors, and officers, and no outside investors exist. specialty pharmaceutical company, today announced that it has relocated re·lo·cate v. re·lo·cat·ed, re·lo·cat·ing, re·lo·cates v.tr. To move to or establish in a new place: relocated the business. v.intr. the Company's corporate headquarters to a new facility at Highland Corporate Park in Cumberland, Rhode Island
Cumberland is a town in Providence County, Rhode Island, USA, incorporated in 1746. The population was 31,840 at the 2000 census. . The site, which is approximately 25,000 square feet, incorporates all of Collegium's administrative functions as well as research and development including analytical laboratories and formulation formulation /for·mu·la·tion/ (for?mu-la´shun) the act or product of formulating. American Law Institute Formulation development. The new facility represents a significant expansion from the Company's prior location in Hingham, Massachusetts Hingham is a town in Plymouth County on the South Shore of Massachusetts. The population was 29,882 at the 2000 census. Hingham is located 8 miles south of the Boston city limits. and will allow the company to support its large number of on-going development projects and increasing staff. "Collegium's move to its new facility reflects our commitment to supporting our rapidly expanding research and development activities. Over the past six months, we have added new staff who directly complement the growth of our specialty pharmaceutical projects. We are pleased to welcome Donald Tibbetts, PhD, as Vice President for Analytical Development," said Jessica Wolfe, PhD, Vice President for Administration, Collegium. Dr. Tibbetts was formerly Director of Quality Control at Copley Pharmaceutical. Prior to that, he held management and research positions at McNeil Consumer Products and Merck. About Collegium Pharmaceutical, Inc. Collegium Pharmaceutical, Inc., is a privately held pharmaceutical company focused on the development of proprietary, late stage pharmaceutical products for the rapidly growing reformulation market and related areas. The Company's products target market opportunities through product improvement and line extension strategies protected by intellectual property (IP), creating a portfolio of improved pharmaceutical products. Collegium uses its broad expertise in IP development, drug formulation, manufacturing, basic science (chemistry, biology, bioengineering bioengineering Application of engineering principles and equipment to biology and medicine. It includes the development and fabrication of life-support systems for underwater and space exploration, devices for medical treatment (see ), marketing and clinical trials management to identify and execute product opportunities across multiple therapeutic areas. For more information, visit the Company's website at www.collegiumpharma.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion